Literature DB >> 22048244

Endophthalmitis following intravitreal injections.

Cristina Irigoyen1, Kimia Ziahosseini, George Morphis, Theodor Stappler, Heinrich Heimann.   

Abstract

BACKGROUND: To report the clinical features, culture results, management and visual outcome of patients with endophthalmitis following intravitreal injections.
METHODS: Retrospective review of all patients with suspected endophthalmitis after intravitreal injections treated with intravitreal antibiotics (teicoplanin and ciprofloxacin) at a referral centre between January 2003 and December 2010.
RESULTS: Nineteen cases that had aqueous or vitreous biopsy were identified. Nine had negative culture. Ten had positive culture; Staphylococcus species in 4/10, Streptococcus species in 4/10, E. coli in 1/10 and gram-negative bacilli in 1/10. Symptoms developed within the first 48 hours in all. One of ten culture-positive cases had no pain on presentation, while 5/9 patients with negative culture reported pain. Initial treatment consisted of intravitreal antibiotics in all cases, 6/19 cases required a second intravitreal antibiotic injection, 4/19 underwent vitrectomy as secondary therapy. At the last follow up, 7/19 patients had visual acuity of 6/18 or better, 9/19 had visual acuity of 6/60 or worse.
CONCLUSION: The overall numbers of patients with endophthalmitis following intravitreal injections has risen dramatically over the past years. In contrast to earlier reports of multicentre studies, outcome of patients is relatively poor in the current treatment settings. We did not find clinical features useful in identifying cases with negative culture.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22048244     DOI: 10.1007/s00417-011-1851-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  27 in total

1.  Toxic vitreitis outbreak after intravitreal injection.

Authors:  Thomas Ness; Niklas Feltgen; Hansjuergen Agostini; Daniel Böhringer; Beate Lubrich
Journal:  Retina       Date:  2010-02       Impact factor: 4.256

2.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.

Authors:  Daphna Mezad-Koursh; Michaella Goldstein; Gad Heilwail; Shiri Zayit-Soudry; Anat Loewenstein; Adiel Barak
Journal:  Retina       Date:  2010 Jul-Aug       Impact factor: 4.256

4.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Authors:  Jeffrey S Heier; David S Boyer; Thomas A Ciulla; Philip J Ferrone; J Michael Jumper; Ronald C Gentile; Debbi Kotlovker; Carol Y Chung; Robert Y Kim
Journal:  Arch Ophthalmol       Date:  2006-11

5.  Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.

Authors:  Colin A McCannel
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

6.  Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.

Authors:  Giuseppe Chisari
Journal:  Curr Clin Pharmacol       Date:  2008-09

7.  Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.

Authors:  K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

8.  Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.

Authors:  Suman Pilli; Athanasios Kotsolis; Richard F Spaide; Jason Slakter; K Bailey Freund; John Sorenson; James Klancnik; Michael Cooney
Journal:  Am J Ophthalmol       Date:  2008-03-10       Impact factor: 5.258

9.  Severe intraocular inflammation after intravitreal injection of bevacizumab.

Authors:  Tatsuhiko Sato; Kazuyuki Emi; Toshihide Ikeda; Hajime Bando; Shigeru Sato; Shin-ichi Morita; Tomohito Oyagi; Kosaku Sawada
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

Review 10.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

View more
  11 in total

Review 1.  Prevention and treatment of injection-related endophthalmitis.

Authors:  Charles Q Yu; Christopher N Ta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-08       Impact factor: 3.117

2.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

3.  Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.

Authors:  D A M Lyall; A Tey; B Foot; S T D Roxburgh; M Virdi; C Robertson; C J MacEwen
Journal:  Eye (Lond)       Date:  2012-10-12       Impact factor: 3.775

Review 4.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Authors:  K Ghasemi Falavarjani; Q D Nguyen
Journal:  Eye (Lond)       Date:  2013-05-31       Impact factor: 3.775

5.  Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.

Authors:  Florian Baudin; Eric Benzenine; Anne-Sophie Mariet; Alain M Bron; Vincent Daien; Jean François Korobelnik; Catherine Quantin; Catherine Creuzot-Garcher
Journal:  JAMA Ophthalmol       Date:  2018-12-01       Impact factor: 7.389

6.  Research on the comparison of the demethylvancomycin's diffusion-deposition characteristics in the ocular solid tissues of sustained subtenon drug delivery with subconjunctival injection.

Authors:  Yi-Qin Duan; Ye-Zhen Yang; Xue-Tao Huang; Ding Lin
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Acute-Onset Endophthalmitis Caused by Alloiococcus otitidis following a Dexamethasone Intravitreal Implant.

Authors:  Tizana Marchino; José I Vela; Francisca Bassaganyas; Saskia Sánchez; José A Buil
Journal:  Case Rep Ophthalmol       Date:  2013-03-07

8.  Incidence and Determinants of Endophthalmitis within 6 Months of Surgeries over a 2-Year Period at King Khaled Eye Specialist Hospital, Saudi Arabia: A Review.

Authors:  Rajiv Khandekar; Saeed Al-Motowa; Hind M Alkatan; Mohammed Karaoui; Anne Ortiz
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun

Review 9.  Endophthalmitis: state of the art.

Authors:  Kamyar Vaziri; Stephen G Schwartz; Krishna Kishor; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-01-08

10.  Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection.

Authors:  Pedro Romero-Aroca; Laura Sararols; Lluis Arias; Ricardo P Casaroli-Marano; Francisca Bassaganyas
Journal:  Clin Ophthalmol       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.